Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 1
1990 7
1992 2
1993 2
1994 3
1995 6
1996 3
1997 6
1998 4
1999 8
2000 5
2001 6
2002 7
2003 8
2004 4
2005 9
2006 2
2007 3
2008 6
2009 3
2010 6
2011 1
2012 1
2013 3
2014 4
2015 2
2016 6
2017 7
2018 11
2019 12
2020 11
2021 16
2022 13
2023 17
2024 11
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Results by year

Filters applied: . Clear all
Page 1
Consensus on diagnosis and management of Cushing's disease: a guideline update.
Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK. Fleseriu M, et al. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20. Lancet Diabetes Endocrinol. 2021. PMID: 34687601 Free PMC article. Review.
Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term management to optimise patient outcomes. The Pituitary Society convened a consensus workshop comprising more than 50 academic researchers and clinical experts to discuss the applicati …
Cushing's disease requires accurate diagnosis, careful treatment selection, and long-term management to optimise patient outcomes. The Pi …
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.
Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson SL, Shimon I, Spencer-Segal J, Vila G, Wass J, Melmed S. Petersenn S, et al. Nat Rev Endocrinol. 2023 Dec;19(12):722-740. doi: 10.1038/s41574-023-00886-5. Epub 2023 Sep 5. Nat Rev Endocrinol. 2023. PMID: 37670148 Review.
This Consensus Statement from an international, multidisciplinary workshop sponsored by the Pituitary Society offers evidence-based graded consensus recommendations and key summary points for clinical practice on the diagnosis and management of prolactinomas. Epidemiology …
This Consensus Statement from an international, multidisciplinary workshop sponsored by the Pituitary Society offers evidence-based g …
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.
Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A; Endocrine Society. Nieman LK, et al. J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31. doi: 10.1210/jc.2015-1818. Epub 2015 Jul 29. J Clin Endocrinol Metab. 2015. PMID: 26222757 Free PMC article.
The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient....
The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), …
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. Brastianos PK, et al. N Engl J Med. 2023 Jul 13;389(2):118-126. doi: 10.1056/NEJMoa2213329. N Engl J Med. 2023. PMID: 37437144 Free PMC article. Clinical Trial.
BACKGROUND: Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or both is often associated with substantial morbidity related to vision loss, neuroendo …
BACKGROUND: Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequ …
ICAR: endoscopic skull-base surgery.
Wang EW, Zanation AM, Gardner PA, Schwartz TH, Eloy JA, Adappa ND, Bettag M, Bleier BS, Cappabianca P, Carrau RL, Casiano RR, Cavallo LM, Ebert CS Jr, El-Sayed IH, Evans JJ, Fernandez-Miranda JC, Folbe AJ, Froelich S, Gentili F, Harvey RJ, Hwang PH, Jane JA Jr, Kelly DF, Kennedy D, Knosp E, Lal D, Lee JYK, Liu JK, Lund VJ, Palmer JN, Prevedello DM, Schlosser RJ, Sindwani R, Solares CA, Tabaee A, Teo C, Thirumala PD, Thorp BD, de Arnaldo Silva Vellutini E, Witterick I, Woodworth BA, Wormald PJ, Snyderman CH. Wang EW, et al. Int Forum Allergy Rhinol. 2019 Jul;9(S3):S145-S365. doi: 10.1002/alr.22326. Int Forum Allergy Rhinol. 2019. PMID: 31329374
RESULTS: The ICAR:ESBS document addresses the role of ESBS in primary cerebrospinal fluid (CSF) rhinorrhea, intradural tumors, benign skull-base and orbital pathology, sinonasal malignancies, and clival lesions. ...CONCLUSION: A critical review of the literature in ESBS de …
RESULTS: The ICAR:ESBS document addresses the role of ESBS in primary cerebrospinal fluid (CSF) rhinorrhea, intradural tumors, benign …
Posterior pituitary tumors and other rare entities involving the pituitary gland.
Roncaroli F, Giannini C. Roncaroli F, et al. Brain Pathol. 2025 Jan;35(1):e13307. doi: 10.1111/bpa.13307. Epub 2024 Sep 30. Brain Pathol. 2025. PMID: 39350562 Free PMC article. Review.
Non-neuroendocrine tumors account for around 10% of all primary neoplasms of the sella. If meningiomas, craniopharyngiomas, and germ cell tumors are excluded, the remaining lesions include a broad spectrum of uncommon, benign, and aggressive, often diagnostically ch …
Non-neuroendocrine tumors account for around 10% of all primary neoplasms of the sella. If meningiomas, craniopharyngiomas, and germ …
Genetic and epigenetic characterization of posterior pituitary tumors.
Schmid S, Solomon DA, Perez E, Thieme A, Kleinschmidt-DeMasters BK, Giannini C, Reinhardt A, Asa SL, Mete O, Stichel D, Siewert C, Dittmayer C, Hasselblatt M, Paulus W, Nagel C, Harter PN, Schittenhelm J, Honegger J, Rushing E, Coras R, Pfister SM, Buslei R, Koch A, Perry A, Jones DTW, von Deimling A, Capper D, Lopes MB. Schmid S, et al. Acta Neuropathol. 2021 Dec;142(6):1025-1043. doi: 10.1007/s00401-021-02377-1. Epub 2021 Oct 18. Acta Neuropathol. 2021. PMID: 34661724 Free PMC article.
Pituicytoma (PITUI), granular cell tumor (GCT), and spindle cell oncocytoma (SCO) are rare tumors of the posterior pituitary. Histologically, they may be challenging to distinguish and have been proposed to represent a histological spectrum of a single entity. ...In …
Pituicytoma (PITUI), granular cell tumor (GCT), and spindle cell oncocytoma (SCO) are rare tumors of the posterior pituitary. …
Fluorescence guided surgery for pituitary adenomas.
Lakomkin N, Van Gompel JJ, Post KD, Cho SS, Lee JYK, Hadjipanayis CG. Lakomkin N, et al. J Neurooncol. 2021 Feb;151(3):403-413. doi: 10.1007/s11060-020-03420-z. Epub 2021 Feb 21. J Neurooncol. 2021. PMID: 33611707 Review.
Both in vitro and in vivo studies were assessed. The application of these agents to pituitary tumors, their advantages and limitations, as well as future directions are presented here. RESULTS: Numerous laboratory and clinical studies have described the use of 5-ALA …
Both in vitro and in vivo studies were assessed. The application of these agents to pituitary tumors, their advantages and lim …
The molecular pathogenesis of craniopharyngiomas.
Campanini ML, Almeida JP, Martins CS, de Castro M. Campanini ML, et al. Arch Endocrinol Metab. 2023 Mar 10;67(2):266-275. doi: 10.20945/2359-3997000000600. Epub 2023 Feb 7. Arch Endocrinol Metab. 2023. PMID: 36748936 Free PMC article. Review.
Besides the well-known clinical and histological differences between the subtypes of CPs, adamantinomatous (ACP) and papillary (PCP) craniopharyngiomas, other molecular differences have been identified, further elucidating pathways related to the origin and development of such …
Besides the well-known clinical and histological differences between the subtypes of CPs, adamantinomatous (ACP) and papillary (PCP) craniop …
Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients.
Guaraldi F, Morandi L, Zoli M, Mazzatenta D, Righi A, Evangelisti S, Ambrosi F, Tonon C, Giannini C, Lloyd RV, Asioli S. Guaraldi F, et al. Clin Endocrinol (Oxf). 2022 Dec;97(6):763-772. doi: 10.1111/cen.14827. Epub 2022 Oct 7. Clin Endocrinol (Oxf). 2022. PMID: 36161330 Free PMC article.
OBJECTIVE: To profile clinically non-aggressive and aggressive pituitary adenomas (PAs)/pituitary neuroendocrine tumours (PitNETs) and pituitary carcinomas for somatic mutations and epigenetic alterations of genes involved in cell proliferation/differentiatio …
OBJECTIVE: To profile clinically non-aggressive and aggressive pituitary adenomas (PAs)/pituitary neuroendocrine tumours (PitN …
204 results